$PSTI The force is strong with this one...
COVID-19
1. kENUP Foundation is currently supporting the following product developments, listed here in alphabetical order, all with the aim to reach patients during 2020:
ChAdOx1 nCoV-19
a replication-deficient simian adenoviral vector vaccine candidate ready for rapid clinical testing.
Under development by the European-based operations of Vaccitech Limited, Oxford and the University of Oxford, with initial vaccine manufacturing anticipated to take place at facilities in the UK and Italy.
COVAX
a measles vector vaccine candidate.
Under development by Themis Bioscience GmbH, Vienna, in cooperation with Institut Pasteur, Paris, with manufacturing anticipated to occur in Germany.
Hydroxychloroquine
repurposing of Hydroxychloroquine for COVID-19 prophylaxis to protect medical staff.
Under development by Pharmakina SA, Democratic Republic of Kongo, in cooperation with the Institute for Tropical Medicine, Travel Medicine, and Human Parasitology, Prof. Dr. Peter Kremsner, of Eberhard Karls Universität Tübingen.
mAbCo19
a therapeutic and prophylactic human monoclonal antibody candidate.
Under development by AchilleS Vaccines Srl Siena, in cooperation with the
laboratory of Dr. Rino Rappuoli, with manufacturing anticipated to occur in Italy
NVX-CoV2373
a RNV vaccine candidate.
Under development by Novavax Inc., and Novavax AB, Uppsala, with both antigen-manufacturing and adjuvant-manufacturing anticipated to occur in the EU.
plant-based protein production
a proprietary plant-based expression platform to mass-produce recombinant antigens and antibodies for use in diagnostics.
Under development by Cape Bio Pharms (Pty.) Ltd., Cape Town.
PLX-PAD
a cell therapy candidate for the treatment of severe pneumonia due to COVID-19.
Under development by Pluristem Ltd., Haifa, and Pluristem GmbH, Berlin.
VPM1002
usage of novel, recombinant BCG vaccine for the prevention of COVID-19 via the induction of trained immunity.
Under development by Serum Institute of India Pvt. Ltd., Bilthoven Biologicals B.V. and Vakzine Projekt Management GmbH (VPM), in cooperation with the Max Planck Institute for Infection Biology, Berlin.
Please dont hesitate to get back to us with any questions or comments you may have. The team can be reached at covid19@kenup.eu.
Last updated on April 9, 2020 at 07:30h
Disclaimer: Information is offered for discussion purposes only and is not guaranteed to be complete, unbiased, current or accurate and is subject to change without notice and is not be relied upon to make any investment decisions.
